259 related articles for article (PubMed ID: 30229512)
1. A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors.
Jimeno A; Moore KN; Gordon M; Chugh R; Diamond JR; Aljumaily R; Mendelson D; Kapoun AM; Xu L; Stagg R; Smith DC
Invest New Drugs; 2019 Jun; 37(3):461-472. PubMed ID: 30229512
[TBL] [Abstract][Full Text] [Related]
2. Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors.
Gordon MS; Nemunaitis J; Barve M; Wainberg ZA; Hamilton EP; Ramanathan RK; Sledge GW; Yue H; Morgan-Lappe SE; Blaney M; Kasichayanula S; Motwani M; Wang L; Naumovski L; Strickler JH
Mol Cancer Ther; 2021 Oct; 20(10):1988-1995. PubMed ID: 34315767
[TBL] [Abstract][Full Text] [Related]
3. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
[TBL] [Abstract][Full Text] [Related]
4. Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
Fu S; Corr BR; Culm-Merdek K; Mockbee C; Youssoufian H; Stagg R; Naumann RW; Wenham RM; Rosengarten RD; Benjamin L; Hamilton EP; Moore KN
J Clin Oncol; 2022 Aug; 40(23):2568-2577. PubMed ID: 35439029
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors.
Luke JJ; Barlesi F; Chung K; Tolcher AW; Kelly K; Hollebecque A; Le Tourneau C; Subbiah V; Tsai F; Kao S; Cassier PA; Khasraw M; Kindler HL; Fang H; Fan F; Allaire K; Patel M; Ye S; Chao DT; Henner WR; Hayflick JS; McDevitt MA; Fong L
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33608377
[TBL] [Abstract][Full Text] [Related]
6. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors.
Chiorean EG; Hurwitz HI; Cohen RB; Schwartz JD; Dalal RP; Fox FE; Gao L; Sweeney CJ
Ann Oncol; 2015 Jun; 26(6):1230-1237. PubMed ID: 25787923
[TBL] [Abstract][Full Text] [Related]
8. ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models.
Yeom DH; Lee YS; Ryu I; Lee S; Sung B; Lee HB; Kim D; Ahn JH; Ha E; Choi YS; Lee SH; You WK
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33383646
[TBL] [Abstract][Full Text] [Related]
9. A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors.
Chiorean EG; LoRusso P; Strother RM; Diamond JR; Younger A; Messersmith WA; Adriaens L; Liu L; Kao RJ; DiCioccio AT; Kostic A; Leek R; Harris A; Jimeno A
Clin Cancer Res; 2015 Jun; 21(12):2695-703. PubMed ID: 25724527
[TBL] [Abstract][Full Text] [Related]
10. Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors.
Haluska P; Menefee M; Plimack ER; Rosenberg J; Northfelt D; LaVallee T; Shi L; Yu XQ; Burke P; Huang J; Viner J; McDevitt J; LoRusso P
Clin Cancer Res; 2014 Sep; 20(18):4747-57. PubMed ID: 25024259
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer.
Saif MW; Knost JA; Chiorean EG; Kambhampati SR; Yu D; Pytowski B; Qin A; Kauh JS; O'Neil BH
Cancer Chemother Pharmacol; 2016 Oct; 78(4):815-24. PubMed ID: 27566701
[TBL] [Abstract][Full Text] [Related]
12. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
Hassan R; Blumenschein GR; Moore KN; Santin AD; Kindler HL; Nemunaitis JJ; Seward SM; Thomas A; Kim SK; Rajagopalan P; Walter AO; Laurent D; Childs BH; Sarapa N; Elbi C; Bendell JC
J Clin Oncol; 2020 Jun; 38(16):1824-1835. PubMed ID: 32213105
[TBL] [Abstract][Full Text] [Related]
13. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors.
Ferrarotto R; Eckhardt G; Patnaik A; LoRusso P; Faoro L; Heymach JV; Kapoun AM; Xu L; Munster P
Ann Oncol; 2018 Jul; 29(7):1561-1568. PubMed ID: 29726923
[TBL] [Abstract][Full Text] [Related]
14. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.
Gordon MS; Sweeney CS; Mendelson DS; Eckhardt SG; Anderson A; Beaupre DM; Branstetter D; Burgess TL; Coxon A; Deng H; Kaplan-Lefko P; Leitch IM; Oliner KS; Yan L; Zhu M; Gore L
Clin Cancer Res; 2010 Jan; 16(2):699-710. PubMed ID: 20068101
[TBL] [Abstract][Full Text] [Related]
15. The bispecific antibody HB-32, blockade of both VEGF and DLL4 shows potent anti-angiogenic activity in vitro and anti-tumor activity in breast cancer xenograft models.
Zhou R; Wang S; Wen H; Wang M; Wu M
Exp Cell Res; 2019 Jul; 380(2):141-148. PubMed ID: 31034805
[TBL] [Abstract][Full Text] [Related]
16. Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors.
Bendell JC; Patel MR; Infante JR; Kurkjian CD; Jones SF; Pant S; Burris HA; Moreno O; Esquibel V; Levin W; Moore KN
Cancer; 2015 Apr; 121(7):1056-63. PubMed ID: 25411085
[TBL] [Abstract][Full Text] [Related]
17. First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors.
Hidalgo M; Martinez-Garcia M; Le Tourneau C; Massard C; Garralda E; Boni V; Taus A; Albanell J; Sablin MP; Alt M; Bahleda R; Varga A; Boetsch C; Franjkovic I; Heil F; Lahr A; Lechner K; Morel A; Nayak T; Rossomanno S; Smart K; Stubenrauch K; Krieter O
Clin Cancer Res; 2018 Apr; 24(7):1536-1545. PubMed ID: 29217526
[No Abstract] [Full Text] [Related]
18. A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors.
Smith DC; Chugh R; Patnaik A; Papadopoulos KP; Wang M; Kapoun AM; Xu L; Dupont J; Stagg RJ; Tolcher A
Invest New Drugs; 2019 Aug; 37(4):722-730. PubMed ID: 30591982
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.
Bilusic M; Heery CR; Collins JM; Donahue RN; Palena C; Madan RA; Karzai F; Marté JL; Strauss J; Gatti-Mays ME; Schlom J; Gulley JL
J Immunother Cancer; 2019 Sep; 7(1):240. PubMed ID: 31488216
[TBL] [Abstract][Full Text] [Related]
20. A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.
Angevin E; Tabernero J; Elez E; Cohen SJ; Bahleda R; van Laethem JL; Ottensmeier C; Lopez-Martin JA; Clive S; Joly F; Ray-Coquard I; Dirix L; Machiels JP; Steven N; Reddy M; Hall B; Puchalski TA; Bandekar R; van de Velde H; Tromp B; Vermeulen J; Kurzrock R
Clin Cancer Res; 2014 Apr; 20(8):2192-204. PubMed ID: 24563479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
